Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet StudyDaniela Cilloni, David Grimwade, Adrian van der Heijden et al.|Journal of Clinical Oncology|2009Cited by 434
Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Blood|2024Cited by 78
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remissionJad Othman, Nigel H. Russell, Nicola Potter et al.|Blood|2024Cited by 75
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Charlotte S. Wilhelm-Benartzi et al.|Journal of Clinical Oncology|2024Cited by 40
Second Primary Non-Myeloid Malignancies Following Intensive Treatment for Adult Acute Myeloid Leukaemia: A Danish Population-Based Cohort StudyNanna Noertoft Nielsen, Marianne Tang Severinsen, Jonas Faartoft Jensen et al.|SSRN Electronic Journal|2024Cited by 0